National Cancer Action Center

Eighty-seven organizations representing patients with chronic and acute health conditions, sent a letter to Congress today urging them to improve the diversity of enrollment in clinical trials as part of this year’s Prescription Drug User Fee Act (PDUFA) reauthorization.

Washington, D.C.--Today ACS CAN filed comments with the Centers for Disease Control and Prevention regarding proposed clinical practice guidelines for prescribing opioids. Read the full comments

National Cancer Institute (NCI) director, Dr. Ned Sharpless, has announced he intends to leave his post at NCI at the end of April. Dr. Sharpless has led the Institute for five years during which time he proved to be a tireless advocate for increased investment in cancer research.

WASHINGTON, D.C.— Monday the Biden administration released its FY 2023 budget, which includes $5 billion for the forthcoming creation of the Advanced Research Project on Health (ARPA-H) but reduces funding by nearly $200 million for the National Cancer Institute (NCI); a scenario which may threaten to undermine the president’s